Navigation Links
OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
Date:5/15/2012

dpoint was non-inferiority based on in-stent late lumen loss at nine months.  The in-stent late lumen loss for the Combo Stent was 0.39 +/- 0.45 mm, compared to 0.44 +/- 0.56 mm for the TAXUS stent. The results were presented late last year during the Late Breaking Clinical Trials and First Report Investigations Session at Transcatheter Cardiovascular Therapeutics (TCT) 2011 in San Francisco. The study's secondary endpoints included clinically driven TLR, binary restenosis, major adverse cardiac events (MACE) and ST rates, as well as all-cause and cardiac mortality, MI and TLF at 30 days, nine months and one through five years.

Ulf Landmesser, M.D., Ph.D., professor of cardiology and head of acute and co-head of invasive cardiology at the Cardiovascular Center, University Hospital of Zurich presented the study design for the REMEDEE OCT trial.

The REMEDEE OCT study will assess vascular healing after deployment of the Combo Stent in patients with acute coronary syndrome (ACS) with single de novo native coronary artery lesions ranging in diameter from greater than or equal to 2.5 mm to less than or equal to 3.5 mm and less than or equal to 20 mm in length. The REMEDEE OCT study, a prospective, multicenter, randomized study, will enroll 60 patients with ACS who will be randomized 1:1 to be treated with the Combo Stent versus the commercially available everolimus eluting stent. The primary endpoint of the study is the percentage of uncovered stent struts per stent at 60 days post procedure determined by OCT. Secondary clinical endpoints include stent thrombosis and major adverse cardiac events (MACE) at 30, 60, 180, 360 and 540 days. MACE is defined as a composite of death, myocardial infarction (MI), emergent coronary artery bypass surgery (CABG), or justified target lesion revascularization (TLR).

"Currently, 55 patients have been enrolled in the REMEDEE OCT study, and we anticipate to complete the enrollment in the next couple of
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
2. Combo method reveals cells signal systems
3. Computer-designed molecules point to new therapy for cystic fibrosis
4. Radiotherapy Clinics of Georgias Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award
5. Valkee and University of Oulu Publish the First Clinical Trial on Bright Light Therapy Channeled via ear Canals in Seasonal Depression
6. Cell Therapy - Technologies, Markets and Companies
7. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
8. Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs
9. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/22/2014)... 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, announced ... University of Calgary in conjunction with co-authors from Kyoto ... validates the company,s ongoing clinical research using dermal sheath ... baldness. The paper entitled " Hair Follicle ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations ... estate, has further expanded its global reach with the ... Western Australia, reports Mylinda Vick, CCIM, Chairman of the ... / ACORPP (Australian Corporate Property and Projects) , is ... services to a wide range of clients in the ...
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... The bread and butter of Wisconsins economic growth will ... capital to transfer our best technology to the marketplace, ... and ensuring theres a 21st century infrastructure in place ... side to the equation, too, that may prove as ...
... a provider of supply chain execution (SCE) ... supplier compliance and inbound productivity by providing ASN ... Link and CatalystConnect SL are part of ... OAG (Open Application Group) XML interface standards. The ...
... WI Governor Jim Doyle today announced his "Grow ... of the recommendations is to increase broadband and ... , ,Mike Tye, AT&T regional vice present of ... encouraged by the "Grow Wisconsin" initiative unveiled today ...
Cached Biology Technology:Athletics, pop culture and the arts 2Athletics, pop culture and the arts 3Software Enables Suppler Customer Data Integration 2
(Date:12/22/2014)... 2014 Research and Markets ... of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... of the global digital media watermarking and ... monitor piracy by securely and invisibly embedding ...
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... Scientific progress in Huntington,s disease (HD) relies upon the ... the disease,s genetics and/or pathophysiology. Large animal models, such ... rodent models, including a larger brain that is amenable ... more human-like neuro-architecture. Three articles in the latest issue ...
... to osteoporosis are a major cause of disability or premature ... who have already suffered one fragility fracture; they are at ... others who have not fractured. Nevertheless health care ... these patients, leaving them exposed to debilitating and life-threatening secondary ...
... and wild plants has concluded they are under threat ... decline or loss could have profound environmental, human health ... services to about 75% of crop species and enable ... Pollination services provided by insects each year worldwide are ...
Cached Biology News:Large animal models of Huntington's disease offer new and promising research options 2Large animal models of Huntington's disease offer new and promising research options 3Large animal models of Huntington's disease offer new and promising research options 4New review sets international standards for best practice in fracture liaison services 2Cocktail of multiple pressures combine to threaten the world's pollinating insects 2
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
TUP1 Market Segment: Molecular Biology...
Biology Products: